Roth Capital Predicts Accuray’s Q1 Earnings (NASDAQ:ARAY)

Accuray Incorporated (NASDAQ:ARAY) – Research analysts at Roth Capital issued their Q1 2026 earnings per share estimates for Accuray in a note issued to investors on Thursday, May 1st. Roth Capital analyst J. Wittes forecasts that the medical equipment provider will post earnings per share of ($0.11) for the quarter. The consensus estimate for Accuray’s current full-year earnings is $0.01 per share. Roth Capital also issued estimates for Accuray’s Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.10) EPS and Q4 2026 earnings at ($0.11) EPS.

Separately, StockNews.com upgraded Accuray from a “hold” rating to a “buy” rating in a report on Friday, April 11th.

Accuray Trading Up 1.1 %

Accuray stock opened at $1.37 on Friday. The company has a market cap of $140.36 million, a price-to-earnings ratio of -27.30 and a beta of 1.30. The firm has a 50-day moving average of $1.70 and a 200-day moving average of $1.93. The company has a debt-to-equity ratio of 3.51, a current ratio of 1.62 and a quick ratio of 0.88. Accuray has a one year low of $1.34 and a one year high of $2.95.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings data on Wednesday, April 30th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.04. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. The company had revenue of $113.24 million for the quarter, compared to the consensus estimate of $101.53 million.

Hedge Funds Weigh In On Accuray

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Heartland Advisors Inc. lifted its stake in Accuray by 14.1% in the 4th quarter. Heartland Advisors Inc. now owns 3,824,750 shares of the medical equipment provider’s stock valued at $7,573,000 after purchasing an additional 472,800 shares during the last quarter. Renaissance Technologies LLC raised its stake in Accuray by 6.8% in the fourth quarter. Renaissance Technologies LLC now owns 2,979,998 shares of the medical equipment provider’s stock valued at $5,900,000 after buying an additional 189,414 shares during the period. Geode Capital Management LLC lifted its position in shares of Accuray by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 2,186,154 shares of the medical equipment provider’s stock valued at $4,329,000 after buying an additional 6,758 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its stake in shares of Accuray by 5.4% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,793,391 shares of the medical equipment provider’s stock worth $3,551,000 after acquiring an additional 91,529 shares during the period. Finally, Acuitas Investments LLC increased its holdings in shares of Accuray by 100.4% during the 1st quarter. Acuitas Investments LLC now owns 1,420,207 shares of the medical equipment provider’s stock worth $2,542,000 after acquiring an additional 711,654 shares during the last quarter. 64.08% of the stock is owned by institutional investors.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.